Display options
Share it on

J Vet Res. 2019 Sep 13;63(3):399-403. doi: 10.2478/jvetres-2019-0051. eCollection 2019 Sep.

Effect of Selected Nonsteroidal Anti-inflammatory Drugs on the Viability of Canine Osteosarcoma Cells of the D-17 Line: .

Journal of veterinary research

Dominik Poradowski, Bożena Obmińska-Mrukowicz

Affiliations

  1. Division of Animal Anatomy, Department of Biostructure and Animal Physiology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 51-631 Wroc?aw, Poland.
  2. Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 50-375 Wroc?aw, Poland.

PMID: 31572821 PMCID: PMC6749731 DOI: 10.2478/jvetres-2019-0051

Abstract

INTRODUCTION: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in veterinary medicine. They are used in pain control and in anti-inflammatory and antipyretic therapies. Some NSAIDs,

MATERIAL AND METHODS: The viability of the cells was evaluated using the MTT assay. Four independent repetitions were performed and the results are given as the average of these values; EC

RESULTS: The analysis of results showed that carprofen and tolfenamic acid displayed the highest cytotoxicity. Other drugs either did not provide such effects or they were very poor. For carprofen, it was possible to determine an EC

CONCLUSION: The results are promising but further studies should be conducted to confirm them, since this study is only preliminary. The possibility of introducing carprofen and tolfenamic acid into the routine treatment of osteosarcoma in dogs should be considered.

© 2019 D. Poradowski, B. Obmińska-Mrukowicz. published by Sciendo.

Keywords: canine osteosarcoma; cytotoxicity assay; dogs; non-steroidal anti-inflammatory drugs

Conflict of interest statement

Conflict of Interest Conflict of Interests Statement: The authors declare that there is no conflict of interests regarding the publication of this article.

References

  1. J Vet Pharmacol Ther. 2007 Dec;30(6):503-7 - PubMed
  2. J Natl Cancer Inst. 2006 Jun 21;98(12):855-68 - PubMed
  3. J Am Vet Med Assoc. 1992 Apr 1;200(7):995-9 - PubMed
  4. J Am Vet Med Assoc. 2007 Oct 1;231(7):1076-80 - PubMed
  5. Urology. 2008 Jan;71(1):156-60 - PubMed
  6. J Vet Intern Med. 2004 Nov-Dec;18(6):859-65 - PubMed
  7. Int J Cancer. 2001 Mar 15;91(6):894-9 - PubMed
  8. Mol Carcinog. 2013 May;52(5):377-86 - PubMed
  9. J Am Vet Med Assoc. 2005 Apr 15;226(8):1364-7 - PubMed
  10. Urology. 2005 Dec;66(6):1239-44 - PubMed
  11. J Vet Intern Med. 2012 Jul-Aug;26(4):977-86 - PubMed
  12. BMC Vet Res. 2014 Sep 05;10:184 - PubMed
  13. Mol Cancer Ther. 2008 Nov;7(11):3539-45 - PubMed
  14. Eur J Pharmacol. 1994 Mar 3;253(3):191-200 - PubMed
  15. J Small Anim Pract. 1996 Aug;37(8):371-5 - PubMed
  16. Invest New Drugs. 2011 Feb;29(1):41-51 - PubMed
  17. Gynecol Oncol. 2011 Jul;122(1):163-70 - PubMed
  18. Cancer Sci. 2011 Apr;102(4):742-8 - PubMed
  19. Carcinogenesis. 2009 Jul;30(7):1193-201 - PubMed
  20. Vet J. 1998 Jul;156(1):31-9 - PubMed

Publication Types